120 related articles for article (PubMed ID: 23136844)
1. Real-time dissolution behavior of furosemide in biorelevant media as determined by UV imaging.
Gordon S; Naelapää K; Rantanen J; Selen A; Müllertz A; Østergaard J
Pharm Dev Technol; 2013; 18(6):1407-16. PubMed ID: 23136844
[TBL] [Abstract][Full Text] [Related]
2. Biorelevant characterisation of amorphous furosemide salt exhibits conversion to a furosemide hydrate during dissolution.
Nielsen LH; Gordon S; Pajander JP; Østergaard J; Rades T; Müllertz A
Int J Pharm; 2013 Nov; 457(1):14-24. PubMed ID: 24050989
[TBL] [Abstract][Full Text] [Related]
3. Biorelevant dissolution of poorly soluble weak acids studied by UV imaging reveals ranges of fractal-like kinetics.
Niederquell A; Kuentz M
Int J Pharm; 2014 Mar; 463(1):38-49. PubMed ID: 24406675
[TBL] [Abstract][Full Text] [Related]
4. Insights into the early dissolution events of amlodipine using UV imaging and Raman spectroscopy.
Boetker JP; Savolainen M; Koradia V; Tian F; Rades T; Müllertz A; Cornett C; Rantanen J; Østergaard J
Mol Pharm; 2011 Aug; 8(4):1372-80. PubMed ID: 21634435
[TBL] [Abstract][Full Text] [Related]
5. Dissolution rate of furosemide from polyethylene glycol solid dispersions.
Ozdemir N; Ordu S
Farmaco; 1997 Oct; 52(10):625-9. PubMed ID: 9507675
[TBL] [Abstract][Full Text] [Related]
6. A discriminatory intrinsic dissolution study using UV area imaging analysis to gain additional insights into the dissolution behaviour of active pharmaceutical ingredients.
Hulse WL; Gray J; Forbes RT
Int J Pharm; 2012 Sep; 434(1-2):133-9. PubMed ID: 22626886
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices.
Lehto P; Aaltonen J; Niemelä P; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
Int J Pharm; 2008 Nov; 363(1-2):66-72. PubMed ID: 18675891
[TBL] [Abstract][Full Text] [Related]
8. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin.
Ozdemir N; Ordu S
Drug Dev Ind Pharm; 1998 Jan; 24(1):19-25. PubMed ID: 15605593
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous UV imaging and raman spectroscopy for the measurement of solvent-mediated phase transformations during dissolution testing.
Østergaard J; Wu JX; Naelapää K; Boetker JP; Jensen H; Rantanen J
J Pharm Sci; 2014 Apr; 103(4):1149-56. PubMed ID: 24496995
[TBL] [Abstract][Full Text] [Related]
10. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
Greco K; Mcnamara DP; Bogner R
J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
[TBL] [Abstract][Full Text] [Related]
11. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
De Zordi N; Moneghini M; Kikic I; Grassi M; Del Rio Castillo AE; Solinas D; Bolger MB
Eur J Pharm Biopharm; 2012 May; 81(1):131-41. PubMed ID: 22266263
[TBL] [Abstract][Full Text] [Related]
12. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media.
Sunesen VH; Pedersen BL; Kristensen HG; Müllertz A
Eur J Pharm Sci; 2005 Mar; 24(4):305-13. PubMed ID: 15734297
[TBL] [Abstract][Full Text] [Related]
13. Effects of oxygen plasma treatment on the surface wettability and dissolution of furosemide compacts.
Naseem A; Olliff CJ; Martini LG; Lloyd AW
J Pharm Pharmacol; 2003 Nov; 55(11):1473-8. PubMed ID: 14713357
[TBL] [Abstract][Full Text] [Related]
14. The effect of buffer species on biorelevant dissolution and precipitation assays - Comparison of phosphate and bicarbonate buffer.
Krollik K; Lehmann A; Wagner C; Kaidas J; Kubas H; Weitschies W
Eur J Pharm Biopharm; 2022 Feb; 171():90-101. PubMed ID: 34592364
[TBL] [Abstract][Full Text] [Related]
15. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates.
Litou C; Vertzoni M; Xu W; Kesisoglou F; Reppas C
Eur J Pharm Biopharm; 2017 Jun; 115():94-101. PubMed ID: 28214603
[TBL] [Abstract][Full Text] [Related]
16. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
Fuchs A; Leigh M; Kloefer B; Dressman JB
Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
[TBL] [Abstract][Full Text] [Related]
17. Supramolecular complexes of maltodextrin and furosemide polymorphs: a new approach for delivery systems.
Garnero C; Chattah AK; Longhi M
Carbohydr Polym; 2013 Apr; 94(1):292-300. PubMed ID: 23544541
[TBL] [Abstract][Full Text] [Related]
18. Real-time UV imaging identifies the role of pH in insulin dissolution behavior in hydrogel-based subcutaneous tissue surrogate.
Jensen SS; Jensen H; Cornett C; Møller EH; Østergaard J
Eur J Pharm Sci; 2015 Mar; 69():26-36. PubMed ID: 25576795
[TBL] [Abstract][Full Text] [Related]
19. Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid.
Takács-Novák K; Szőke V; Völgyi G; Horváth P; Ambrus R; Szabó-Révész P
J Pharm Biomed Anal; 2013 Sep; 83():279-85. PubMed ID: 23770783
[TBL] [Abstract][Full Text] [Related]
20. Surface Dissolution UV Imaging for Investigation of Dissolution of Poorly Soluble Drugs and Their Amorphous Formulation.
Long CM; Tang K; Chokshi H; Fotaki N
AAPS PharmSciTech; 2019 Feb; 20(3):113. PubMed ID: 30761437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
